Alopecia Areata Clinical Trial
Official title:
Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser Versus Microneedling in Alopecia Areata Treatment
Alopecia areata (AA) an autoimmune disorder of hair follicles results in varying degrees of scalp, facial and body hair loss. Clinically, patients' presentation varies from patchy circumscribed scalp involvement to total body and scalp hair loss affects up to 2% of the general population. The exact pathobiology of AA has still remained elusive, while the common theory is the collapse of the immune privilege of the hair follicle caused by immunological mechanism. Multiple genetic, environment factors and psychological stress contribute to the pathogenesis of Alopecia Areata . Recent insights into the pathogenesis of AA have led to the development of new treatment strategies, such as Janus kinase inhibitors, biologics and several small molecular agents. In addition, modern therapies for AA, including antihistamines, platelet-rich plasma injection
Latanoprost is a prostaglandin analogue with well-established efficacy in the treatment of open-angle glaucoma and ocular hypertension. Make an increase in the number, thickness and length of eyelashes is an important side effect of latanoprost eye drop. This study aimed to evaluate the effect of hypertrichosis property of latanoprost in the treatment of scalp Alopecia Areata. Numerous techniques and agents such as microneedling, dermabrasion, radiofrequency and lasers have been used to increase penetration within an approach known as transdermal drug delivery. One of these techniques is laser-assisted drug delivery (LADD), which often uses ablative fractional lasers (CO2 or erbium: YAG lasers) because of their capacity to produce microscopic ablated channels. LADD is a promising technique that enhances the absorption of topical molecules while adding the synergic effect. Microneedling is a form of therapy that utilizes instruments that contain rows of thin needles that penetrate the dermis to uniform depth, creating a controlled skin injury. Transcutaneous drug delivery via fractional laser and microneedling is a promising modality with preliminary evidence for increased hair regrowth over topical therapy alone. Trichoscopy is a noninvasive procedure performed in dermatology clinics and is a helpful tool in determining the correct diagnosis of hair loss presentations. The five most characteristic trichoscopic findings in AA are yellow dots, black dots, broken hairs, short vellus hairs and tapering hairs. Also trichoscopy is a useful tool that allows monitoring of response during treatment of AA. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05051761 -
Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
|
Phase 3 | |
Active, not recruiting |
NCT03570749 -
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
|
Phase 2/Phase 3 | |
Completed |
NCT02812342 -
Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants
|
Phase 2 | |
Completed |
NCT02350023 -
Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata
|
Phase 4 | |
Completed |
NCT02018042 -
An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata
|
Phase 2 | |
Terminated |
NCT01898806 -
Intralesional Steroids in the Treatment of Alopecia Areata
|
Phase 4 | |
Recruiting |
NCT04011748 -
Clinical Application of Stem Cell Educator Therapy in Alopecia Areata
|
Phase 2 | |
Terminated |
NCT04517864 -
PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA
|
Phase 2 | |
Not yet recruiting |
NCT05803070 -
Topical Cetirizine in Treatment of Localized Alopecia Areata
|
||
Not yet recruiting |
NCT05496426 -
A Study of KL130008 in Adults With Severe Alopecia Areata
|
Phase 2 | |
Completed |
NCT04147845 -
Transepidermal Delivery of Triamcinolone Acetonide or Platelet Rich Plasma Using Either Fractional Carbon Dioxide Laser or Microneedling in Treatment of Alopecia Areata
|
N/A | |
Terminated |
NCT03325296 -
Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.
|
Phase 2 | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Enrolling by invitation |
NCT05745389 -
CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
|
||
Recruiting |
NCT04246372 -
Tofacitinib for Immune Skin Conditions in Down Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT06087796 -
Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata.
|
Phase 1 | |
Withdrawn |
NCT03532958 -
Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
|
Phase 2 | |
Recruiting |
NCT02604888 -
Efficacy Study of a Cosmetic Lotion in the Treatment of Alopecia Areata in Males and Females
|
N/A | |
Terminated |
NCT01385839 -
Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata
|
N/A | |
Completed |
NCT00408798 -
Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin
|
N/A |